The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

They showed that patients with mild Alzheimer’s disease who received an older, similar medication (liraglutide, sold under the brand name Victoza), had slower declines in both their cognition and ...

Katharine Lang reports Glucagon-like peptide-1 (GLP-1) receptor agonist drugs such as liraglutide (Saxenda) and semaglutide (Ozempic, Wegovy) are being hailed as game changers in treating adult ...

All 79 websites sold compounded semaglutide and 72.2 and 3.8 percent sold compounded tirzepatide and liraglutide, respectively. Overall, 52 websites featured a mark of certification; 50 displayed ...

The FDA approved Hikma's first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1) receptor agonist indicated to improve glycemic ...

Liraglutide, the generic for Victoza, is similar to semaglutide, the active ingredient in the popular weight-loss drug Ozempic. The FDA supports the development of generic drugs, such as GLP-1s ...